CIP
ALDR

Chartwell Investment Partners’s Alder Biopharmaceuticals ALDR Stock Holding History

Chartwell Investment Partners’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-101,010
Closed -$2.1M – 433
2017
Q1 		$2.1M Sell
101,010
-4,561
-4% -$101K 0.08% 283
2016
Q4 		$2.2M Buy
+105,571
New +$2.75M 0.07% 304

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Chartwell Investment Partners's ALDR Position: Q2 2017 in Review

Chartwell Investment Partners sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 101,010 shares — an estimated $2.1M sold.

Chartwell Investment Partners first reported a position in ALDR in Q4 2016 and held it in 2 quarters. The position peaked at $2.2M in Q4 2016. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

  • Chartwell Investment Partners reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Chartwell Investment Partners sold 101,010 Alder Biopharmaceuticals shares in Q2 2017, an estimated $2.1M.
  • Chartwell Investment Partners first reported a position in Alder Biopharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Chartwell Investment Partners's Alder Biopharmaceuticals position peaked at $2.2M in Q4 2016.
  • 128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on Chartwell Investment Partners's 13F filing for Q2 2017, filed 4 Aug 2017.